Liu, Ilon http://orcid.org/0000-0002-6186-3630
Jiang, Li
Samuelsson, Erik R. http://orcid.org/0000-0002-5622-288X
Marco Salas, Sergio
Beck, Alexander
Hack, Olivia A.
Jeong, Daeun
Shaw, McKenzie L.
Englinger, Bernhard
LaBelle, Jenna
Mire, Hafsa M.
Madlener, Sibylle
Mayr, Lisa
Quezada, Michael A. http://orcid.org/0000-0001-7307-5204
Trissal, Maria
Panditharatna, Eshini
Ernst, Kati J.
Vogelzang, Jayne
Gatesman, Taylor A.
Halbert, Matthew E.
Palova, Hana
Pokorna, Petra http://orcid.org/0000-0003-1037-878X
Sterba, Jaroslav
Slaby, Ondrej
Geyeregger, Rene
Diaz, Aaron http://orcid.org/0000-0001-9059-9501
Findlay, Izac J.
Dun, Matthew D.
Resnick, Adam
Suvà, Mario L. http://orcid.org/0000-0001-9898-5351
Jones, David T. W.
Agnihotri, Sameer
Svedlund, Jessica
Koschmann, Carl
Haberler, Christine
Czech, Thomas
Slavc, Irene http://orcid.org/0000-0002-9419-6790
Cotter, Jennifer A. http://orcid.org/0000-0002-1420-3314
Ligon, Keith L. http://orcid.org/0000-0002-7733-600X
Alexandrescu, Sanda
Yung, W. K. Alfred
Arrillaga-Romany, Isabel
Gojo, Johannes
Monje, Michelle http://orcid.org/0000-0002-3547-237X
Nilsson, Mats http://orcid.org/0000-0001-9985-0387
Filbin, Mariella G. http://orcid.org/0000-0002-2613-8126
Article History
Received: 28 October 2021
Accepted: 20 October 2022
First Online: 5 December 2022
Competing interests
: M.G.F. is a consultant for Twentyeight-Seven Therapeutics and Blueprint Medicines. M.N. is Scientific Advisor for 10X Genomics. M.M. is a SAB member for Cygnal Therapeutics. M.L. Suvà is an equity holder, scientific cofounder and advisory board member of Immunitas Therapeutics. K.L.L. is the founder and equity holder of Travera and receives consulting fees from BMS, Integragen, Rarecyte and research support from Lilly, BMS and Amgen. J.S. is now (but not when contributing to this manuscript) an employee of 10X Genomics. The remaining authors declare no competing interests.